Cargando…

Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis

BACKGROUND: Approximately 50% of human epidermal growth factor receptor 2 (HER2)-positive breast cancer lesions express hormone receptors. These tumors present a unique therapeutic challenge, and the optimal endocrine therapeutic approach remains controversial. We aimed to study the optimal adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peleg Hasson, S., Brezis, M.R., Shachar, E., Shachar, S.S., Wolf, I., Sonnenblick, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988286/ https://www.ncbi.nlm.nih.gov/pubmed/33735801 http://dx.doi.org/10.1016/j.esmoop.2021.100088

Ejemplares similares

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]
por: Peleg Hasson, S., et al.
Publicado: (2021)

Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
por: Raphael, Ari, et al.
Publicado: (2022)

Kambô-Induced Systemic Inflammatory Response: A Case Report of Acute Disease Progression of Cholangiocarcinoma
por: Peleg Hasson, Shira, et al.
Publicado: (2021)

Rapid Implementation of Telemedicine During the COVID‐19 Pandemic: Perspectives and Preferences of Patients with Cancer
por: Hasson, Shira Peleg, et al.
Publicado: (2021)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
por: Feldman, Didi, et al.
Publicado: (2023)

Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes
por: Peleg Hasson, Shira, et al.
Publicado: (2020)

Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis
por: Peleg Hasson, Shira, et al.
Publicado: (2022)

Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database
por: Nahleh, Zeina A, et al.
Publicado: (2020)

OTHR-03. Brain Metastasis Among Ovarian Cancer Patients
por: Limon, Dror, et al.
Publicado: (2021)

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
por: Mata, Danilo Giffoni de Mello Morais, et al.
Publicado: (2022)

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
por: Salvo, Elizabeth M., et al.
Publicado: (2021)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

The impact of tumor detection method on genomic and clinical risk and chemotherapy recommendation in early hormone receptor positive breast cancer
por: Bar, Yael, et al.
Publicado: (2021)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer
por: Waissengrin, B., et al.
Publicado: (2022)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
por: Gao, Hong-Fei, et al.
Publicado: (2021)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer
por: James, Rani, et al.
Publicado: (2011)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Rosso, Roberta, et al.
Publicado: (2023)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023)

Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Shimoi, Tatsunori, et al.
Publicado: (2020)

Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
por: Montagna, Emilia, et al.
Publicado: (2019)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
por: Ferrando, Lorenzo, et al.
Publicado: (2023)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
por: Lambert, Leah K., et al.
Publicado: (2018)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
por: López González, Ana, et al.
Publicado: (2022)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
por: Liao, Hao, et al.
Publicado: (2022)

Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
por: Basho, Reva K., et al.
Publicado: (2018)

Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_av7qp31obboipbrhvdsl5vv6il